The key details to know:
1. The pharmacy chain agreed to pay more than $269 million to resolve allegations it improperly billed Medicare and Medicaid for hundreds of thousands of insulin pens beneficiaries didn’t need. Walgreens falsely stated that what was dispensed didn’t exceed a patient’s daily prescription, according to prosecutors. The company’s electronic management system also prevented pharmacists from dispensing partial insulin pens, even when the patient didn’t require a larger dose, prosecutors said.
2. In a separate action brought against the company, Walgreens agreed to pay $60 million. Prosecutors alleged that Walgreens overcharged federal healthcare programs for medications dispensed through its Prescription Savings Program.
3. The state of New York will receive $14.5 million as part of the settlement. In a statement to the New York Law Journal, Walgreens said it admitted no wrongdoing and fully cooperated with the government.
More articles on coding, billing and collections:
Group Insurance Commission lowers copays to drive patients to ASCs: 3 details
3 ways to ensure coding & billing accuracy at your ASC
5 key ASC price transparency do’s and don’ts to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
